Biofidelity confirms scientific advisory board as it heads towards launch of ASPYRE-Lung diagnostic test
Biofidelity has confirmed the initial members of its new scientific advisory board, who will help guide its molecular diagnostic products.
The Cambridge Science Park company has appointed:
- Dr Mace Rothenberg, former CMO, Pfizer
- Dr Hesham Abdullah, head of oncology global clinical development, GSK
- Dr Jerald Radich, professor and Kurt Enslein endowed chair, Fred Hutchinson Cancer Research Center
- Andrea Conners, executive director, Patient Empowerment Network
- Phylicia L Woods, executive director, Cancer Policy Institute, Cancer Support Community
Biofidelity’s ASPYRE technology enables simple, decentralised multi-gene testing in a fraction of the time and at a fraction of the cost of current technologies.
It has the ability to perform the ultra-sensitive detection of panels of DNA and RNA mutations from tissue or blood using existing real-time PCR platforms, offering actionable results in hours.
It expects to launch its first commercial diagnostic assay, ASPYRE-Lung - formerly Identi-Lung - later this year through its recently established US headquarters and cancer diagnostic laboratory in Research Triangle Park, NC.
CEO Dr Barnaby Balmforth said: “Biofidelity’s disruptive technology is designed to revolutionise access to best-in-class cancer diagnostics, breaking down barriers to better screening, monitoring and treatment for all cancer patients.
“Dr Mace Rothenberg, Dr Hesham Abdullah and Dr Jerald Radich have an extraordinary track record of service to cancer patients at the world’s leading pharmaceutical companies and research centres, while Andrea Conners and Phylicia Woods have been tremendous advocates for patients and for access to precision medicine.
“We are greatly honoured and encouraged by their commitment to support the potential of ASPYRE to provide oncologists with rapid, clinically actionable data to enable the right cancer treatment to be prescribed at the right time.”
Read more
Biofidelity moves to larger Cambridge Science Park HQ and appoints Dr Robert Osborne as COO
Biofidelity’s $12m will help it transform cancer diagnostics
Winners of Cambridge Independent Science and Technology Awards revealed
Sign up for our weekly newsletter and get the latest on Cambridge life sciences direct to your inbox every Friday